drugset / Trial / NCT00529113
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.
Timeline
- Start
- 2007-09-30
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
Outcome
Outcome not reported
Stopped: “To pursue other indications”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bardoxolone methyl | Small molecule | 150 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 200 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 250 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 300 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 350 mg | Oral |
| Background | 1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15 | Unknown | 1000 mg/m2 | Intravenous |